Bristol -Myers Squibb News

Don’t suffer the equities markets, buy XFR (BMY Debt Trust)

Motley Fool - 1 hour ago
Don’t suffer the equities markets, buy XFR The equity and debt markets are topsy turvy from the surprises and pressure from the credit crisis. Investors, scared of their own shadow regarding debt ...

Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepat

Bristol Myers (BMY) PriceWatch Alert for February 17, 2009

Market Intelligence Center - 1 hour ago
Bristol Myers (NYSE: BMY) closed yesterday at $21.75. So far the stock has hit a 52-week low of $16.00 and 52-week high of $23.98. Bristol Myers stock has been showing support around 20.88 and ...

Bristol Myers (BMY) PriceWatch Alert - Calendar Spread Risk Ranking Declines to 3 Keys

AstraZeneca and BMS expand alliance

Alibaba News Channel - 16 minutes ago
AstraZeneca and Bristol-Myers Squibb (BMS) recently announced the expansion of their worldwide collaboration to include the development and commercialisation of Dapagliflozin in Japan ...

FDA’s Latest Drug Safety List Includes Abilify, Plan B

FDA news (subscription) - 54 minutes ago
Postmarketing surveillance by the FDA revealed potential risks of heart and blood disorders associated with Bristol-Myers Squibb and Otsuka’s schizophrenia drug Abilify. Abilify (aripiprazole) was ...

Bristol-Myers To IPO Baby Formula Biz (BMY, MJN)

Investopedia - 38 minutes ago
Despite the terrible investment climate for equities, Bristol-Myers Squibb (NYSE:BMY), along with a few other intrepid companies, is dipping its toes into the ice-cold waters of public share ...

Operations management software to add competitive edge to biopharma plant

ZymoGenetics Retains a Buy Rec

Trading Markets (press release) - 17 minutes ago
Feb 14, 2009 (Zacks Investment Research via COMTEX) -- BMY | Quote | Chart | News | PowerRating -- Highlights include ZymoGenetics (ZGEN) and Bristol-Myers Squibb (BMY).ZymoGenetics: Buy on Strong ...

Invasive Strategy Among Women With Non–ST-Elevation Acute Coronary Syndrome (Invasive Strategy Among Women With Non–ST-Elevation ACS)